Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1302 in Treatment-naïve Graves' Disease (Phase IIa)
CTR20260071Phase 2Active
- Sponsor
- Baiming Xinkang
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of WP1302 in Graves' disease, sponsored by Baiming Xinkang. Started Jan 2026; status: active.
02
Drugs
WP1302
03
Conditions
Graves' disease
Beyond the preview
Go deeper on CTR20260071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260071.